Dupixent is covered by most major insurance plans, including commercial insurance, Medicare Part D, and Medicaid, but coverage almost always comes with conditions. You’ll likely need prior authorization, meaning your doctor must submit paperwork proving the medication is medically necessary before your plan agrees to pay. The process can take days to weeks, and denials are common enough that it’s worth understanding what insurers look for and what financial help exists if your out-of-pocket costs are still high.
What Insurance Plans Typically Require
Dupixent is a specialty biologic with a list price over $30,000 per year, so insurers treat it differently than a standard prescription. Nearly all plans place it on a high specialty drug tier, which means higher copays or coinsurance and stricter approval rules. Coverage varies by plan type, but the general pattern is the same: your prescriber submits a prior authorization request, the insurer reviews it against a set of clinical criteria, and you either get approved, denied, or asked for more information.
Most plans also require Dupixent to be filled through a specialty pharmacy rather than a regular retail pharmacy. This is standard for biologics and usually means the medication is shipped directly to your home on a set schedule.
Step Therapy: Treatments You Must Try First
The biggest hurdle for most patients is step therapy. Insurers want to see that you’ve already tried and failed cheaper treatments before they’ll approve Dupixent. The specific requirements depend on your condition.
For atopic dermatitis (eczema), plans typically require documented failure of at least two types of topical therapies. This usually means medium- to high-potency topical corticosteroids for the body, lower-potency steroids for the face, or topical calcineurin inhibitors. An “adequate trial” generally means using the topical treatment once or twice daily for at least four weeks. Some plans, particularly Medicaid programs, go further and require that you’ve also tried phototherapy and systemic immunosuppressants before they’ll cover Dupixent.
For asthma, you need to show that your symptoms remain uncontrolled despite maximum doses of standard controller medications. Plans also require lab work confirming an eosinophilic phenotype, typically a blood eosinophil count of 150 cells per microliter or higher. For COPD, the eosinophil threshold is higher at 300 cells per microliter, and you’ll need lung function test results showing specific levels of airflow limitation.
Other approved conditions have their own step therapy rules. Eosinophilic esophagitis requires a biopsy showing eosinophil-driven inflammation and a failed eight-week trial of acid-reducing medication. Prurigo nodularis requires documentation of at least 20 nodular lesions and prior treatment failures. Chronic spontaneous urticaria requires trying at least two antihistamines for a minimum of two weeks.
All Eight FDA-Approved Conditions
Insurance will only cover Dupixent for conditions the FDA has approved it to treat. As of 2025, there are eight:
- Atopic dermatitis in patients 6 months and older with moderate-to-severe disease
- Asthma in patients 6 years and older with an eosinophilic phenotype or oral steroid dependence
- Chronic rhinosinusitis with nasal polyps in patients 12 and older
- Eosinophilic esophagitis in patients 1 year and older weighing at least 15 kg
- Prurigo nodularis in adults
- COPD in adults with an eosinophilic phenotype
- Chronic spontaneous urticaria in patients 12 and older
- Bullous pemphigoid in adults
If your doctor prescribes Dupixent for a condition not on this list, your insurer will almost certainly deny coverage.
Common Reasons for Denial
Denials don’t always mean your insurer won’t cover Dupixent. They often mean the paperwork wasn’t complete. The most common reasons include missing test results (eosinophil counts, lung function values, biopsy findings), incomplete documentation of previous treatments you’ve tried, or a prescription from a provider type the plan doesn’t accept. Some plans restrict Dupixent prescriptions to specialists like dermatologists, pulmonologists, or gastroenterologists, so a prescription from a primary care doctor may be rejected on that basis alone.
Other denial reasons include the drug not being on your plan’s formulary at all, your diagnosis not matching the plan’s approved list, or a known contraindication flagged in your medical record.
How to Appeal a Denial
If your prior authorization is denied, start by requesting the specific reason from your insurer. Then work with your prescriber to fill in whatever’s missing. A strong appeal includes your exact diagnosis, a measure of disease severity, the names and doses of every treatment you’ve previously tried, how long you used each one, why you stopped (side effects, lack of improvement), and any relevant lab results or imaging.
For asthma appeals, this means including eosinophil counts, exhaled nitric oxide levels, and lung function values alongside documentation of symptom flares or emergency visits. For eczema, it means detailing which topical steroids and immunosuppressants you’ve used and for how long. The more specific the documentation, the better the chance of reversal.
Copay Assistance for Commercially Insured Patients
Even with insurance approval, your coinsurance on a specialty-tier drug can be substantial. The Dupixent MyWay copay card covers a significant portion of out-of-pocket costs for commercially insured patients, with a maximum benefit of $13,000 per year. This card is not available to patients on Medicare, Medicaid, or other government-funded insurance.
The copay card effectively brings many patients’ costs down to $0 per fill, though this depends on your plan’s coinsurance percentage and whether $13,000 covers the gap. Your specialty pharmacy or the Dupixent MyWay program can estimate your actual cost before you fill your first prescription.
Free Medication for Eligible Patients
If you’re uninsured or underinsured, Sanofi (the manufacturer) offers Dupixent at no cost through its Patient Connection program. Eligibility is based on household income: you must earn no more than 400% of the federal poverty level. For 2026, that means a single person earning up to $63,840 or a family of four earning up to $132,000 in the continental U.S. The thresholds are higher in Alaska ($79,800 for one person, $165,000 for four) and Hawaii ($73,440 for one person, $151,800 for four). For households larger than eight, add roughly $5,680 to $7,100 per additional person depending on your state.
This program is separate from the copay card and is designed for patients who either lack insurance entirely or whose insurance doesn’t cover Dupixent. You apply through the Sanofi Patient Connection website, and approval typically requires proof of income and insurance status.